Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20943764 | 0.87 | NLRP3 (0.51) | RAD52TLR7 | |
| SCHEMBL9038851 | 0.86 | PARP1 (0.57) | TLR7TLR8PARP1 | |
| SCHEMBL20943799 | 0.84 | RAD52 (0.38) | RAD52TLR7TLR8 | |
| SCHEMBL9036182 | 0.83 | TLR7 (0.52) | TLR7TLR8PARP1 | |
| SCHEMBL20968370 | 0.83 | TERT (0.44) | RAD52TLR7TLR8PARP1TERT | |
| SCHEMBL20968317 | 0.83 | PARP1 (0.41) | TLR7TLR8PARP1 | |
| SCHEMBL20970190 | 0.83 | RAD52 (0.43) | RAD52TLR7TLR8POLB | |
| SCHEMBL20943755 | 0.82 | TLR7 (0.43) | RAD52TLR7TLR8PARP1 | |
| SCHEMBL20970129 | 0.82 | RAD52 (0.42) | RAD52TLR7TLR8 | |
| SCHEMBL20970113 | 0.82 | RAD52 (0.42) | RAD52TLR7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-11072612-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157097-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10556903-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556903-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190127367-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127367-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2017184746-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184746-A1 | NLRP3 MODULATORS | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11072612-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | RAD52 4422/4885TLR7 161/4885TLR8 196/4885 |
| US-20200157097-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | RAD52 4422/4885TLR7 161/4885TLR8 196/4885 |
| US-10556903-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | RAD52 4422/4885TLR7 161/4885TLR8 196/4885 |
| US-20190127367-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | RAD52 4746/4885TLR7 207/4885TLR8 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.